I can't really say.
I will say however that we should not read too much into undemonstrated speculations (at least not to the point of taking potentially dangerous medications).
This is nearly ALL in early stage research. None of it is suitable for advocating serious medical approaches. The only exceptions in the near future are likely to be Rituximab and Ampligen.
The other "problem" is that Ron Davis and those he is cooperating with are moving toward an open data and fast research approach. This is a good thing. However it means that preliminary findings are probably less reliable early on. False positives will be higher, as will false negatives. Yet in time this is probably the fastest way to make progress. Its a departure from traditional methods, and we need to consider that in interpreting data.
Historically good medical science has started with an hypothesis or exploratory reseach proposal, a grant application, a grant, then the study, then analysis, then write-up, then publication review, possible rewrite, then publication, then widespread review by other scientists.
For clinical application you then repeat those steps, first with phase 1 trials, then phase 2, then phase 3, then ongoing drug or treatment monitoring. Its a long slow road. All of this can take upwards of 20 years if a new drug has to be invented. It can cost over a billion dollars.
The Ron Davis approach is similar to the concept of rapid prototyping in programming. He is doing one experiment a week, not per several years, and wants to increase that to multiple studies a week. Eventually these will form a pattern, and the combination may be published formally, but I am not sure that is an intention. Immediate scientific release of data changes the whole picture. Traditional ways of looking at scientific results will not completely apply. Any scientist can get the raw data and run their own analysis.
This is open research at its most cutting edge. There will be mistakes. There will be corrections. There will be experiments to test previous conclusions. Eventually there may be a phase 3 trial of something, I am not sure how open medical research can currently get around that.